Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors By Brandon Tilley|2023-12-31T10:55:19+00:00December 18, 2023|News|0 Comments Read More
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma By Brandon Tilley|2023-12-31T10:51:58+00:00December 14, 2023|News|0 Comments Read More
The Logical Song: Biolojic Design Reimagines Antibodies into “Smart” Therapeutics By Brandon Tilley|2023-07-18T14:26:23+00:00August 23, 2022|News|0 Comments Read More
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients By Brandon Tilley|2023-06-22T18:15:25+00:00April 5, 2022|News|0 Comments Read More
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes By Brandon Tilley|2023-06-22T18:16:10+00:00March 8, 2021|News|0 Comments Read More
Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease By Brandon Tilley|2023-06-22T18:16:59+00:00February 25, 2021|News|0 Comments Read More
Biolojic’s anti IL2 antibody covered in Nature’s review of current IL2 therapies in development By Brandon Tilley|2023-06-20T20:59:31+00:00February 21, 2021|Publication|0 Comments Read More
